Home / Precision Medicine (page 20)

Precision Medicine

AstraZeneca Announces its Integrated Genomics Approach to Transform Drug Discovery and Development

AstraZeneca and its global biologics research and development arm, MedImmune, today announced an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline. The initiative includes new collaborations with Human Longevity, Inc., US; the Wellcome Trust Sanger Institute, UK, and The Institute for Molecular …

Read More »

Agena Bioscience Launches Genetic Testing Product for Targeted Analysis of Solid Tumors

SAN DIEGO, April 18, 2016 /PRNewswire/ — Today Agena Bioscience announced the commercial availability of iPLEX® HS, a new chemistry that enables highly sensitive, multiplexed detection of genetic variants present in solid tumors. iPLEX HS, unveiled today at the American Association of Cancer Research conference, provides cancer researchers a unique …

Read More »

Plasma Genotyping to Predict Treatment Benefit in Patients with NSCLC

GENEVA, Switzerland, 15 April 2016 – The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 Researchers however warned that plasma tests are unlikely to fully …

Read More »

Flatiron Health Partners with Celgene and Amgen to Advance Personalized Medicine for Cancer Patients

NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced an expansion of its relationships with Celgene Corporation and Amgen Inc. Through individual agreements, Celgene and Amgen will collaborate with Flatiron Health with the goals of accelerating clinical research, advancing personalized medicine and enhancing treatment options for cancer patients. In addition, Celgene Switzerland LLC …

Read More »

Three Glycosyltransferases Identified as Significant Mutational Targets in Colon Cancer

Little is known about the molecular basis of aberrant protein glycosylation, a complex enzymatic process that is a hallmark of many human cancers including colorectal cancers (CRC), and how it may contribute to tumor progression. In a new study published in Scientific Reports, an online journal of the Nature Publishing …

Read More »

BioGenex Launches Two New Antibodies for Cancer Diagnosis

FREMONT, Calif., April 4, 2016 /PRNewswire/ — BioGenex, a global leader and innovator in molecular pathology and cancer diagnostics, announced the release of two new antibodies for the diagnosis of cancer. The new antibodies against PMS2 (clone EP51) and CK5 (clone EP24), are rabbit polyclonal immunohistochemistry (IHC) grade antibodies and …

Read More »

GSK’s New Gene Therapy Receives Positive CHMP Opinion in Europe for Treatment of ADA-SCID

GlaxoSmithKline (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has issued a positive opinion recommending marketing authorisation for Strimvelis to treat patients with a very rare disease called ADA-SCID …

Read More »

New Tool Mines Whole-Exome Sequencing Data to Match Cancer with Best Drug

A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association (JAMIA) describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches the cancer’s unique genetics to FDA-approved targeted treatments. “Whole exome sequencing is becoming more available …

Read More »

Forge Therapeutics and Active Motif Enter Epigenetics Research Collaboration

SAN DIEGO, March 28, 2016 /PRNewswire/ — Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins, and Active Motif, a leader in developing tools to enable epigenetics research, announced today a research collaboration aimed at advancing epigenetic research related to the family …

Read More »

Lupus Study Shows Precision Medicine’s Potential to Define the Genetics of Autoimmune Disease

DALLAS – March 18, 2016 – Demonstrating the potential of precision medicine, an international study based at UT Southwestern Medical Center used next-generation DNA sequencing technology to identify more than 1,000 gene variants that affect susceptibility to systemic lupus erythematosus (SLE). Precision medicine is an emerging field that aims to deliver …

Read More »